Servier and Oncodesign have announced a strategic partnership for the research and development of potential drug candidates for Parkinson’s disease.   This research and development partnership involves the LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix platform, and their potential to act as therapeutic agents against Parkinson’s disease.    According to the terms of the agreement, Oncodesign and Servier will collaborate to ensure the succe...